Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream in plaque psoriasis
NCT00778700Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2008
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Incyte
- Modality
- Small Molecules
- Drugs
- ruxolitinib cream
- Conditions
- plaque psoriasis
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib cream in plaque psoriasis (4 arms), sponsored by Incyte. Primary endpoint: Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions at Day 84. Started Oct 2008; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Vehicle Cream
Vehicle cream applied once daily
Ruxolitinib 0.5%
Ruxolitinib phosphate 0.5% cream applied once daily
Ruxolitinib 1.0%
Ruxolitinib phosphate 1.0% cream applied once daily
Ruxolitinib 1.5%
Ruxolitinib phosphate 1.5% cream applied once daily
03
Who it enrols
Patients with stable plaque psoriasis involving 2-20% BSA, excluding those with lesions solely on intertriginous areas/scalp/face, pustular psoriasis, or erythroderma. Patients must not be on systemic therapy or other topical agents/UVB within 2 weeks.
04
Endpoints
Primary
Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions
Secondary
Absolute Change From Baseline in the Individual Lesion Scores for Lesion Thickness
Absolute Change From Baseline in the Individual Lesion Scores for Lesion Erythema
Absolute Change From Baseline in the Individual Lesion Scores for Lesion Scaling
Percentage of Participants Achieving None (Score=0) and Mild (Score=1) in Lesion Thickness
Percentage of Participants Achieving None (Score=0) and Mild (Score=1) in Lesion Erythema
Percentage of Participants Achieving None (Score=0) and Mild (Score=1) in Lesion Scaling
Absolute Change From Baseline in the Percent Treatable Body Surface Area (BSA)
Absolute Change From Baseline in the Physician's Global Assessment (PGA) Score
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT00778700.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778700.